Dermatol. praxi. 2022;16(4):199-203 | DOI: 10.36290/der.2022.040

Diagnosis of autoimmune bullous diseases

prof. MUDr. Hana Jedličková, Ph.D.
Dermatovenerologická klinika FN u sv. Anny v Brně a LF MU, Brno

Autoimmune blistering diseases are rare organ-specific autoimmune diseases characterized by autoantibodies against desmosomal and hemidesmosomal adhesive proteins of epidermis. They can be divided into two main groups - pemphigus group with intraepidermal blisters and pemphigoid group with subepidermal blisters. Correct diagnosis of the subtypes is based on a complex of clinical observation, histopatological and immunofluorescence examinations, detection of circulating autoantibodies by indirect immunofluorescence, enzyme-linked immunosorbent assay (ELISA) and immunoblotting, thus allowing the precise diagnosis and the choice of appropriate therapy.

Keywords: pemphigus, pemphigoid, histology, immunofluorescence, ELISA.

Accepted: November 29, 2022; Published: December 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Jedličková H. Diagnosis of autoimmune bullous diseases. Dermatol. praxi. 2022;16(4):199-203. doi: 10.36290/der.2022.040.
Download citation

References

  1. Jedličková H. Autoimunitní bulózní intradermální dermatózy. In Moderní farmakoterapie v dermatologii. Praha, Maxdorf; 1. vydání: 2020, p. 432-436.
  2. Jedličková H. Autoimunitní bulózní subepidermální dermatózy. In: Moderní farmakoterapie v dermatologii, Benáková N. a kol Praha, Maxdorf; 1.vydání: 2020, p. 205-209.
  3. Saschenbrecker S, Karl I, Komorowski L, et al. Serological Diagnosis of Autoimmune Bullous Skin Diseases. Front. Immunol. 2019 10. Available from DOI=10.3389/fimmu.2019.01974 Go to original source... Go to PubMed...
  4. Koga H, Prost-Squarcioni C, Iwata H, et al. Epidermolysis Bullosa Acquisita: The 2019 Update. Front. Med. 2019 5. Available from DOI=10.3389/fmed.2018.00362 Go to original source... Go to PubMed...
  5. Chaudhari S, Mobini N. Linear IgA Bullous Dermatosis: A Rare Clinicopathologic Entity with an Unusual Presentation. J Clin Aesthet Dermatol. 2015 Oct;8(10):43-46.
  6. Van Beek N, Kruege S, Fuhrmann T, et al. Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology. J Am Acad Derm. 2020;80(5):1315-1332. Go to original source... Go to PubMed...
  7. Hashimoto T, Teye K, Hashimoto K, et al. Clinical and Immunological Study of 30 Cases With Both IgG and IgA Anti-Keratinocyte Cell Surface Autoantibodies Toward the Definition of Intercellular IgG/IgA Dermatosis. Front. Immunol. 9. Available from https://www.frontiersin.org/articles/10.3389/fimmu.2018.00994.
  8. Nandiwada SL, Tebo AE. Testing for antireticulin antibodies in patients with celiac disease is obsolete: a review of recommendations for serologic screening and the literature. Clin Vaccine Immunol. 2013;20(4):447-51. doi: 10.1128/CVI.00568-12. Go to original source... Go to PubMed...
  9. Hertl M. Pemphigus. In: Autoimmune diseases of the skin, Hertl M (ed.) Wien New York, Springer; 2005. p.45-48. Go to original source...
  10. Saschenbrecker S, Karl I, Komorowski L, et al. Serological Diagnosis of Autoimmune Bullous Skin Diseases. Front. Immunol. 2019 10. Available from DOI=10.3389/fimmu.2019.01974 Go to original source... Go to PubMed...
  11. Hanušová K, Jedličková H. Autoimunitní puchýřnatá onemocnění - současné možnosti diagnostiky. Alergie. 2018;20(3):170-177.
  12. Chaudhari S, Mobini N. Linear IgA Bullous Dermatosis: A Rare Clinicopathologic Entity with an Unusual Presentation. J Clin Aesthet Dermatol. 2015;8(10):43-46.
  13. Chen M, Hallel-Halevy D, Nadelman C. et al. Epidermolysis bullosa acquisita. In: Autoimmune diseases of the skin, Hertl M (ed.) Wien New York, Springer; 2005:109-112 Go to original source...
  14. Hanušová K, Jedličková H. Autoimunitní puchýřnatá onemocnění - současné možnosti diagnostiky. Alergie. 2018;20(3):170-177.




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.